All 1 tracked stories fall under one category: market-trends. IQVIA Holdings is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Charles River Laboratories appears in 1 tracked Healthcare story from June 19, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Charles River Laboratories
All 1 tracked stories fall under one category: market-trends. IQVIA Holdings is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Charles River Laboratories appears in 1 tracked Healthcare story from June 19, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Charles River Laboratories. Shared-story counts are live from our verified record — not editorial picks.
Morgan Stanley’s upgrade of Charles River and downgrade of IQVIA signal a shift in healthcare R&D outsourcing. CROs with deep ties to small biotech stands to gain as venture funding rebounds, potentially accelerating drug development timelines and altering cost structures for health systems.
Charles River Laboratories is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.